Mitochondrial DNA variants correlate with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Billing Ross, Paul ^a   Germain, Arnaud ^a   Ye, Kaixiong ^a   Keinan, Alon ^a   Gu, Zhenglong ^a   Hanson, Maureen R ^a  

^a Division of Nutritional Sciences ^*  (United States)

Author keywords

Association; Chronic fatigue syndrome (CFS); Haplogroup; Heteroplasmy; Mitochondrial DNA; MtDNA; Myalgic encephalomyelitis (ME); Next generation sequencing; SNPs; Variants

Indexed keywords

MITOCHONDRIAL DNA; GENETIC MARKER;

ADULT; ARTICLE; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOGROUP; HEALTH STATUS; HETEROPLASMY; HUMAN; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL GENOME; SEQUENCE ANALYSIS; SHORT FORM 36; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; ALLELE; COHORT ANALYSIS; GENETIC ASSOCIATION STUDY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; MIDDLE AGED; MUTATION; YOUNG ADULT;

ADULT; AGED; ALLELES; COHORT STUDIES; DNA, MITOCHONDRIAL; FATIGUE SYNDROME, CHRONIC; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84955243580     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-0771-6     Document Type: Article

References (45)

1. Hutchinson CV, Maltby J, Badham SP, Jason LA. Vision-related symptoms as a clinical feature of chronic fatigue syndrome/myalgic encephalomyelitis? Evidence from the DePaul Symptom Questionnaire. Br J Ophthalmol. 2014;98(1):144-5. doi: 10.1136/bjophthalmol-2013-304439.
2. Jason LA, Evans M, Porter N, Brown M, Brown A, Hunnell J, et al. The development of a revised Canadian myalgic encephalomyelitis-chronic fatigue syndrome case definition. Am J Biochem Biotechnol. 2010;6:120-35.
3. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Int Med. 2000;160:221-7.
4. Komaroff AL, Buchwald D. Symptoms and signs of chronic fatigue syndrome. Rev Infect Dis. 1991;13(Suppl 1):S8-11.
5. Myhill S, Booth NE, McLaren-Howard J. Targeting mitochondrial dysfunction in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-a clinical audit. Int J Clin Exp Med. 2013;6(1):1-15.
6. Vermeulen RC, Kurk RM, Visser FC, Sluiter W, Scholte HR. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. J Transl Med. 2010;8:93. doi: 10.1186/1479-5876-8-93.
7. Smits B, van den Heuvel L, Knoop H, Kusters B, Janssen A, Borm G, et al. Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome. Mitochondrion. 2011;11(5):735-8. doi: 10.1016/j.mito.2011.05.005.
8. Plioplys AV, Plioplys S. Electron-microscopic investigation of muscle mitochondria in chronic fatigue syndrome. Neuropsychobiology. 1995;32(4):175-81.
9. Castro-Marrero J, Cordero MD, Saez-Francas N, Jimenez-Gutierrez C, Aguilar-Montilla FJ, Aliste L, et al. Could mitochondrial dysfunction be a differentiating marker between chronic fatigue syndrome and fibromyalgia? Antiox. Redox Sig. 2013;19(15):1855-60. doi: 10.1089/ars.2013.5346.
10. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro endocrinol Lett. 2009;30(4):470-6.
11. Hollingsworth KG, Jones DE, Taylor R, Blamire AM, Newton JL. Impaired cardiovascular response to standing in chronic fatigue syndrome. Eur J Clin Invest. 2010;40(7):608-15. doi: 10.1111/j.1365-2362.2010.02310.x.
12. Lane RJ, Barrett MC, Taylor DJ, Kemp GJ, Lodi R. Heterogeneity in chronic fatigue syndrome: evidence from magnetic resonance spectroscopy of muscle. Neuromuscul Dis. 1998;8(3-4):204-9.
13. Wong R, Lopaschuk G, Zhu G, Walker D, Catellier D, Burton D, et al. Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest. 1992;102(6):1716-22.
14. McCully KK, Smith S, Rajaei S, Leigh JS Jr, Natelson BH. Blood flow and muscle metabolism in chronic fatigue syndrome. Clin Sci. 2003;104(6):641-7. doi: 10.1042/CS20020279.
15. McCully KK, Smith S, Rajaei S, Leigh JS Jr, Natelson BH. Muscle metabolism with blood flow restriction in chronic fatigue syndrome. J Appl Phys. 2004;96(3):871-8. doi: 10.1152/japplphysiol.00141.2003.
16. Wallace DC. Mitochondrial DNA mutations in disease and aging. Environ Mol Mutagen. 2010;51(5):440-50. doi: 10.1002/em.20586.
17. Fuku N, Park KS, Yamada Y, Nishigaki Y, Cho YM, Matsuo H, et al. Mitochondrial haplogroup N9a confers resistance against type 2 diabetes in Asians. Am J Hum Genet. 2007;80(3):407-15. doi: 10.1086/512202.
18. Boles RG, Hornung HA, Moody AE, Ortiz TB, Wong SA, Eggington JM, et al. Hurt, tired and queasy: specific variants in the ATPase domain of the TRAP1 mitochondrial chaperone are associated with common, chronic "functional" symptomatology including pain, fatigue and gastrointestinal dysmotility. Mitochondrion. 2015;23:64-70. doi: 10.1016/j.mito.2015.05.002.
19. Boles RG, Zaki EA, Kerr JR, Das K, Biswas S, Gardner A. Increased prevalence of two mitochondrial DNA polymorphisms in functional disease: are we describing different parts of an energy-depleted elephant? Mitochondrion. 2015;23:1-6.
20. Ye K, Lu J, Ma F, Keinan A, Gu Z. Extensive pathogenicity of mitochondrial heteroplasmy in healthy human individuals. Proc Natl Acad Sci USA. 2014;111(29):10654-9. doi: 10.1073/pnas.1403521111.
21. de Laat P, Koene S, van den Heuvel LP, Rodenburg RJ, Janssen MC, Smeitink JA. Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A>G mutation. J Inherit Metab Dis. 2012;35(6):1059-69. doi: 10.1007/s10545-012-9465-2.
22. Klimas NG, Ironson G, Carter A, Balbin E, Bateman L, Felsenstein D, et al. Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome. Fatigue. 2015;3:75-96. doi: 10.1080/21641846.2015.1023652.
23. Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the medical outcomes study. Med Care. 1995;33(4 Suppl):AS264-79.
24. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121(12):953-9.
25. Carruthers BM, Jain AK, DeMeirleir KL, Peterson DL, Klimas NG, Lerner AM, et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatments protocols. J Chronic Fatigue Synd. 2003;11:7-115.
26. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international Consensus Criteria. J Int Med. 2011;270(4):327-38. doi: 10.1111/j.1365-2796.2011.02428.x.
27. Jason LA, So S, Brown AA, Sunnquist M, Evans ME. Test-retest reliability of the DePaul symptom questionnaire. Fatigue. 2015;3:16-32. doi: 10.1080/21641846.2014.978110.
28. Brown AA, Jason LA. Validating a measure of myalgic encephalomyelitis/chronic fatigue syndrome symptomatology. Fatigue. 2014;2:132-52.
29. Lyons EA, Scheible MK, Sturk-Andreaggi K, Irwin JA, Just RS. A high-throughput Sanger strategy for human mitochondrial genome sequencing. BMC Genomics. 2013;14:881. doi: 10.1186/1471-2164-14-881.
30. Li H, Durbin R. Inference of human population history from individual whole-genome sequences. Nature. 2011;475(7357):493-6. doi: 10.1038/nature10231.
31. Bandelt HJ, Kloss-Brandstatter A, Richards MB, Yao YG, Logan I. The case for the continuing use of the revised cambridge reference sequence (rCRS) and the standardization of notation in human mitochondrial DNA studies. J Hum Genet. 2014;59:66-77.
32. Dayama G, Emery SB, Kidd JM, Mills RE. The genomic landscape of polymorphic human nuclear mitochondrial insertions. Nuc Acids Res. 2014;42(20):12640-9. doi: 10.1093/nar/gku1038.
33. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(16):2078-9. doi: 10.1093/bioinformatics/btp352.
34. Kloss-Brandstatter A, Pacher D, Schonherr S, Weissensteiner H, Binna R, Specht G, et al. HaploGrep: a fast and reliable algorithm for automatic classification of mitochondrial DNA haplogroups. Hum Mutat. 2011;32:25-32. doi: 10.1002/humu.21382.
35. van Oven M, Kayser M. Updated comprehensive phylogenetic tree of global human mitochondrial DNA variation. Hum Mutat. 2009;30(2):E386-94.
36. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Human Genet. 2007;81:559-75. doi: 10.1086/519795.
37. Benjamini Y, Hochberg Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J Roy Stat Soc B Met. 1995;57:289-300.
38. Goto H, Dickins B, Afgan E, Paul IM, Taylor J, Makova KD, et al. Dynamics of mitochondrial heteroplasmy in three families investigated via a repeatable re-sequencing study. Genome Biol. 2011;12:R59. doi: 10.1186/gb-2011-12-6-r59.
39. Hornig M, Montoya JG, Klimas NG, Levine S, Felsenstein D, Bateman L, et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv. 2015;1:e1400121. doi: 10.1126/sciadv.1400121.
40. Chinnery PF, Brown DT, Andrews RM, Singh-Kler R, Riordan-Eva P, Lindley J, et al. The mitochondrial ND6 gene is a hot spot for mutations that cause Leber's hereditary optic neuropathy. Brain. 2001;124(Pt 1):209-18.
41. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nature Genet. 2014;46(3):310-5. doi: 10.1038/ng.2892.
42. Urzúa-Traslaviña CG, Moreno-Treviño MG, Martínez-Treviño DA, Barrera-Saldaña HA, León-Cachón RBR. Relationship of mitochondrial DNA haplogroups with complex diseases. J Genet Genome Res. 2014;1:2.
43. Baudouin SV, Saunders D, Tiangyou W, Elson JL, Poynter J, Pyle A, et al. Mitochondrial DNA and survival after sepsis: a prospective study. Lancet. 2005;366(9503):2118-21.
44. Hart AB, Samuels DC, Hulgan T. The other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy. AIDS Rev. 2013;15(4):213-20.
45. Mueller EE, Brunner SM, Mayr JA, Stanger O, Sperl W, Kofler B. Functional differences between mitochondrial haplogroup T and haplogroup H in HEK293 cybrid cells. PLoS One. 2012;7:e52367.